Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia. (2016)

First Author: Liberante FG
Attributed to:  Gene-expression connectivity mapping and its application in phenotypic targeting funded by BBSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.18632/oncotarget.6773

PubMed Identifier: 26735888

Publication URI: http://europepmc.org/abstract/MED/26735888

Type: Journal Article/Review

Volume: 7

Parent Publication: Oncotarget

Issue: 6

ISSN: 1949-2553